http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2022515248-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2601-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2601-06 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C311-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-603 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-167 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C311-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2019-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-02-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2022515248-A |
| titleOfInvention | Novel salicylic acid derivative, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof |
| abstract | To inhibit STAT3 and / or STAT5 activity using novel compounds, compositions containing them and compounds of formula I or pharmaceutically acceptable salts, solvates or hydrates thereof. Alternatively, with respect to methods for treating cell proliferation disorders such as cancer, R and R 1 are different in the formula and are selected from the group consisting of —H, (Ia), (Ib) and (Ic). When one of R and R 1 is -H, the other of R and R 1 is the cyclopentyl moiety, R 2 is a benzyl substituted with 1-5 halogens, preferably -Cl, -F or -Br. And R 3 is selected from the group consisting of —H or —OH. |
| priorityDate | 2018-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 23.